391 related articles for article (PubMed ID: 30142389)
1. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
Metaxas Y; Rivalland G; Mauti LA; Klingbiel D; Kao S; Schmid S; Nowak AK; Gautschi O; Bartnick T; Hughes BG; Bouchaab H; Rothschild SI; Pavlakis N; Wolleb S; Petrausch U; O'Byrne K; Froesch P; Löffler-Baumann M; Pratsch-Peter S; Russell P; Mingrone W; Savic S; Thapa B; Früh M; Pless M; von Moos R; John T
J Thorac Oncol; 2018 Nov; 13(11):1784-1791. PubMed ID: 30142389
[TBL] [Abstract][Full Text] [Related]
2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
Pasello G; Zago G; Lunardi F; Urso L; Kern I; Vlacic G; Grosso F; Mencoboni M; Ceresoli GL; Schiavon M; Pezzuto F; Pavan A; Vuljan SE; Del Bianco P; Conte P; Rea F; Calabrese F
Ann Oncol; 2018 May; 29(5):1258-1265. PubMed ID: 29514216
[TBL] [Abstract][Full Text] [Related]
3. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
Chapel DB; Stewart R; Furtado LV; Husain AN; Krausz T; Deftereos G
Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study.
Yap TA; Nakagawa K; Fujimoto N; Kuribayashi K; Guren TK; Calabrò L; Shapira-Frommer R; Gao B; Kao S; Matos I; Planchard D; Chatterjee A; Jin F; Norwood K; Kindler HL
Lancet Respir Med; 2021 Jun; 9(6):613-621. PubMed ID: 33836153
[TBL] [Abstract][Full Text] [Related]
5. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Avelumab Treatment in Patients With Advanced Unresectable Mesothelioma: Phase 1b Results From the JAVELIN Solid Tumor Trial.
Hassan R; Thomas A; Nemunaitis JJ; Patel MR; Bennouna J; Chen FL; Delord JP; Dowlati A; Kochuparambil ST; Taylor MH; Powderly JD; Vaishampayan UN; Verschraegen C; Grote HJ; von Heydebreck A; Chin K; Gulley JL
JAMA Oncol; 2019 Mar; 5(3):351-357. PubMed ID: 30605211
[TBL] [Abstract][Full Text] [Related]
7. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in.
Nowak AK; Lesterhuis WJ; Kok PS; Brown C; Hughes BG; Karikios DJ; John T; Kao SC; Leslie C; Cook AM; Pavlakis N; Briscoe K; O'Byrne KJ; Karapetis CS; Lam WS; Langford A; Yip S; Stockler MR
Lancet Oncol; 2020 Sep; 21(9):1213-1223. PubMed ID: 32888453
[TBL] [Abstract][Full Text] [Related]
8. Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
Alley EW; Lopez J; Santoro A; Morosky A; Saraf S; Piperdi B; van Brummelen E
Lancet Oncol; 2017 May; 18(5):623-630. PubMed ID: 28291584
[TBL] [Abstract][Full Text] [Related]
9. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
Bronte G; Delmonte A; Burgio MA; Verlicchi A; Puccetti M; Bravaccini S; Cravero P; Tumedei MM; Diano D; Rossi G; Ulivi P; Martinelli G; Crinò L
Lung Cancer; 2020 Apr; 142():47-50. PubMed ID: 32088605
[TBL] [Abstract][Full Text] [Related]
10. Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
Patil NS; Righi L; Koeppen H; Zou W; Izzo S; Grosso F; Libener R; Loiacono M; Monica V; Buttigliero C; Novello S; Hegde PS; Papotti M; Kowanetz M; Scagliotti GV
J Thorac Oncol; 2018 Jan; 13(1):124-133. PubMed ID: 29079455
[TBL] [Abstract][Full Text] [Related]
11. Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab.
Minchom A; Yuan W; Crespo M; Gurel B; Figueiredo I; Wotherspoon A; Miranda S; Riisnaes R; Ferreira A; Bertan C; Pereira R; Clarke M; Baker C; Ang JE; Fotiadis N; Tunariu N; Carreira S; Popat S; O'Brien M; Banerji U; de Bono J; Lopez J
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32169873
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
13. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
14. A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
Popat S; Curioni-Fontecedro A; Dafni U; Shah R; O'Brien M; Pope A; Fisher P; Spicer J; Roy A; Gilligan D; Gautschi O; Nadal E; Janthur WD; López Castro R; García Campelo R; Rusakiewicz S; Letovanec I; Polydoropoulou V; Roschitzki-Voser H; Ruepp B; Gasca-Ruchti A; Peters S; Stahel RA
Ann Oncol; 2020 Dec; 31(12):1734-1745. PubMed ID: 32976938
[TBL] [Abstract][Full Text] [Related]
15. Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Metaxas Y; Früh M; Eboulet EI; Grosso F; Pless M; Zucali PA; Ceresoli GL; Mark M; Schneider M; Maconi A; Perrino M; Biaggi-Rudolf C; Froesch P; Schmid S; Waibel C; Appenzeller C; Rauch D; von Moos R;
Ann Oncol; 2020 Apr; 31(4):495-500. PubMed ID: 32085891
[TBL] [Abstract][Full Text] [Related]
16. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
Cedrés S; Ponce-Aix S; Pardo-Aranda N; Navarro-Mendivil A; Martinez-Marti A; Zugazagoitia J; Sansano I; Montoro MA; Enguita A; Felip E
Lung Cancer; 2016 Jun; 96():1-6. PubMed ID: 27133741
[TBL] [Abstract][Full Text] [Related]
17. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
Brosseau S; Danel C; Scherpereel A; Mazières J; Lantuejoul S; Margery J; Greillier L; Audigier-Valette C; Gounant V; Antoine M; Moro-Sibilot D; Rouquette I; Molinier O; Corre R; Monnet I; Langlais A; Morin F; Bergot E; Zalcman G; Levallet G
Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
[TBL] [Abstract][Full Text] [Related]
18. Clinical outcomes in non-small cell lung cancer patients with an ultra-high expression of programmed death ligand-1 treated using pembrolizumab as a first-line therapy: A retrospective multicenter cohort study in Japan.
Edahiro R; Kanazu M; Kurebe H; Mori M; Fujimoto D; Taniguchi Y; Suzuki H; Hirano K; Yokoyama T; Morita M; Fukuda Y; Uchida J; Makio T; Tamiya M
PLoS One; 2019; 14(7):e0220570. PubMed ID: 31365588
[TBL] [Abstract][Full Text] [Related]
19. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
Kao SC; Cheng YY; Williams M; Kirschner MB; Madore J; Lum T; Sarun KH; Linton A; McCaughan B; Klebe S; van Zandwijk N; Scolyer RA; Boyer MJ; Cooper WA; Reid G
J Thorac Oncol; 2017 Sep; 12(9):1421-1433. PubMed ID: 28629895
[TBL] [Abstract][Full Text] [Related]
20. Prediction of patients with a tumor proportion score > 50% who do not respond to first-line monotherapy with pembrolizumab.
Morita M; Tamiya M; Fujimoto D; Tamiya A; Suzuki H; Hirano K; Fukuda Y; Yokoyama T; Kominami R; Kanazu M; Uchida J; Hara S; Yamashita S; Tomioka H
BMC Cancer; 2020 Feb; 20(1):93. PubMed ID: 32013910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
